UTHSCSA - Faculty Profiles

Search All | Profile | Publications | Grants | Faculty Index

Thompson, Jr., Ian Murchie Jr.

School of Medicine
Urology
(210) 567-5643
thompsoni@uthscsa.edu

Dr. Thompsons primary research interest is in the early detection and prevention of cancers of the genitourinary tract. He is Chairman of the Early Detection Research Network of the National Cancer Institute. He is principal Investigator of SABOR, San Antonio Centers for Biomarkers of Risk of Prostate Cancer. This study is sponsored by NCI and follows a 4,500 subject cohort for the discovery and validation of new biomarkers for Prostate Cancer.

Appointments Education Expertise Teaching Publications Grants

12/2010 - Present	Director	Cancer Therapy & Research Center, San Antonio, TX
9/1992 - Present	Clinical Associate Professor	Department of Surgery /Uniformed Services of Health Sciences, Surgery, Bethesda, MD

Journal Article

Thompson IM, Leach R, Thompson, Jr. IM. Prostate Cancer and Prostatic Intraepithelial Neoplasia: True, True, and Unrelated? J Clin Oncol 2013 Jan;.

Schenk JM, Calip GS, Tangen CM, Goodman P, Parsons JK, Thompson IM, Kristal AR, Thompson, Jr. IM. Indications for and use of nonsteroidal antiinflammatory drugs and the risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial Am J Epidemiol 2012 Jul;176(2):156-163.

Klein EA, Thompson IM. Chemoprevention of prostate cancer: an updated view World J Urol 2012 Apr;30(2):189-194.

Berglund RK, Tangen CM, Powell IJ, Lowe BA, Haas GP, Carroll PR, Canby-Hagino ED, deVere White R, Hemstreet GP, Crawford ED, Thompson IM, Klein EA. Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: update on Southwest Oncology Group Study 9109 Urology 2012 Mar;79(3):633-637.

Hilton WM, Padalecki SS, Ankerst DP, Leach RJ, Thompson IM, Thompson, Jr. IM. Temporal changes in the clinical approach to diagnosing prostate cancer J Natl Cancer Inst Monogr 2012 Jan;2012(45):162-168.

Chokkalingam AP, Yeboah ED, Demarzo A, Netto G, Yu K, Biritwum RB, Tettey Y, Adjei A, Jadallah S, Li Y, Chu LW, Chia D, Niwa S, Partin A, Thompson IM, Roehrborn C, Hoover RN, Hsing AW. Prevalence of BPH and lower urinary tract symptoms in West Africans Prostate Cancer Prostatic Dis 2011 Sep;.

Ankerst DP, Pollock BH, Liang Y, Dizdarevic N, Kyrylenko S, Boeck A, Thompson IM, Leach R. Trends and co-trends of prostate-specific antigen and body mass index in a screened population Urology 2011 Jul;78(1):10-16.

Rim SH, Hall IJ, Fairweather ME, Fedorenko CR, Ekwueme DU, Smith JL, Thompson IM, Keane TE, Penson DF, Moinpour CM, Zeliadt SB, Ramsey SD. Considering racial and ethnic preferences in communication and interactions among the patient, family member, and physician following diagnosis of localized prostate cancer: study of a US population Int J Gen Med 2011 Jun;4:481-486.

Schenk JM, Kristal AR, Arnold KB, Tangen CM, Neuhouser ML, Lin DW, White E, Thompson IM. Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial Am J Epidemiol 2011 Jun;173(12):1419-1428.

Yao S, Till C, Kristal AR, Goodman PJ, Hsing AW, Tangen CM, Platz EA, Stanczyk FZ, Reichardt JK, Tang L, Neuhouser ML, Santella RM, Figg WD, Price DK, Parnes HL, Lippman SM, Thompson IM, Ambrosone CB, Hoque A. Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial: a nested case-control study Cancer Causes Control 2011 Jun;.

Brasky TM, Till C, White E, Neuhouser ML, Song X, Goodman P, Thompson IM, King IB, Albanes D, Kristal AR. Serum phospholipid Fatty acids and prostate cancer risk: results from the prostate cancer prevention trial Am J Epidemiol 2011 Jun;173(12):1429-1439.

Dorff TB, Flaig TW, Tangen CM, Hussain MH, Swanson GP, Wood DP, Sakr WA, Dawson NA, Haas NB, Crawford ED, Vogelzang NJ, Thompson IM, Glode LM. Adjuvant Androgen Deprivation for High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921 Study J Clin Oncol 2011 May;29(15):2040-2045.

Smith DC, Tangen CM, Van Veldhuizen PJ, Harrer GW, Golshayan A, Mills GM, Vogelzang NJ, Thompson IM, Hussain MH. Phase II evaluation of early oral estramustine, oral etoposide, and intravenous paclitaxel combined with hormonal therapy in patients with high-risk metastatic prostate adenocarcinoma: Southwest Oncology Group S0032 Urology 2011 May;77(5):1172-1176.

Thompson IM, Ozawa M, Bubolz JW, Yang Q, Dahl GE. Bovine luteal prolactin receptor expression: potential involvement in regulation of progesterone during the estrous cycle and pregnancy J Anim Sci 2011 May;89(5):1338-1346.

Kristal AR, Till C, Platz EA, Song X, King IB, Neuhouser ML, Ambrosone CB, Thompson IM. Serum lycopene concentration and prostate cancer risk: results from the Prostate Cancer Prevention Trial Cancer Epidemiol Biomarkers Prev 2011 Apr;20(4):638-646.

Hardman RL, El-Merhi F, Jung AJ, Ware S, Thompson IM, Friel HT, Peng Q. Fast T2*-weighted MRI of the prostate at 3 Tesla J Magn Reson Imaging 2011 Apr;33(4):902-907.

Ramsey SD, Zeliadt SB, Fedorenko CR, Blough DK, Moinpour CM, Hall IJ, Smith JL, Ekwueme DU, Fairweather ME, Thompson IM, Keane TE, Penson DF. Patient preferences and urologist recommendations among local-stage prostate cancer patients who present for initial consultation and second opinions World J Urol 2011 Feb;29(1):3-9.

Zeliadt SB, Penson DF, Moinpour CM, Blough DK, Fedorenko CR, Hall IJ, Smith JL, Ekwueme DU, Thompson IM, Keane TE, Ramsey SD. Provider and partner interactions in the treatment decision-making process for newly diagnosed localized prostate cancer BJU Int 2011 Jan;.

Kristal AR, Arnold KB, Neuhouser ML, Goodman P, Platz EA, Albanes D, Thompson IM. Diet, supplement use, and prostate cancer risk: results from the prostate cancer prevention trial Am J Epidemiol 2010 Sep;172(5):566-577.

Thompson IM, Ankerst DP, Tangen CM. Prostate-Specific Antigen, Risk Factors, and Prostate Cancer: Confounders Nestled in an Enigma J Natl Cancer Inst 2010 Aug;.

Zeliadt SB, Moinpour CM, Blough DK, Penson DF, Hall IJ, Smith JL, Ekwueme DU, Thompson IM, Keane TE, Ramsey SD. Preliminary treatment considerations among men with newly diagnosed prostate cancer Am J Manag Care 2010 May;16(5):121-130.

Sokoll LJ, Sanda MG, Feng Z, Kagan J, Mizrahi IA, Broyles DL, Partin AW, Srivastava S, Thompson IM, Wei JT, Zhang Z, Chan DW. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness Cancer Epidemiol Biomarkers Prev 2010 May;19(5):1193-1200.

Schenk JM, Kristal AR, Neuhouser ML, Tangen CM, White E, Lin DW, Kratz M, Thompson IM. Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial Am J Epidemiol 2010 Mar;171(5):571-582.

Wolf AM, Wender RC, Etzioni RB, Thompson IM, D''Amico AV, Volk RJ, Brooks DD, Dash C, Guessous I, Andrews K, DeSantis C, Smith RA. American Cancer Society guideline for the early detection of prostate cancer: update 2010 CA Cancer J Clin 2010 Mar;60(2):70-98.

Sutcliffe S, Viscidi RP, Till C, Goodman PJ, Hoque AM, Hsing AW, Thompson IM, Zenilman JM, De Marzo AM, Platz EA. Human papillomavirus types 16, 18, and 31 serostatus and prostate cancer risk in the Prostate Cancer Prevention Trial Cancer Epidemiol Biomarkers Prev 2010 Feb;19(2):614-618.

Beuten J, Gelfond JA, Franke JL, Shook S, Johnson-Pais TL, Thompson IM, Leach RJ. Single and multivariate associations of MSR1, ELAC2 and RNASEL with prostate cancer in an ethnic diverse cohort of men Cancer Epidemiol Biomarkers Prev 2010 Feb;19(2):588-599.

Liang Y, Ankerst DP, Sanchez M, Leach RJ, Thompson IM. Body mass index adjusted prostate-specific antigen and its application for prostate cancer screening Urology 2010 Jan;76(5):1261-1266.

Teichman JM, Sea J, Thompson IM, Elston DM. Noninfectious penile lesions Am Fam Physician 2010 Jan;81(2):167-174.

Beuten J, Garcia D, Brand TC, He X, Balic I, Canby-Hagino E, Troyer DA, Baillargeon J, Hernandez J, Thompson IM, Leach RJ, Naylor SL. Semaphorin 3B and 3F single nucleotide polymorphisms are associated with prostate cancer risk and poor prognosis J Urol 2009 Oct;182(4):1614-1620.

Eyre SJ, Ankerst DP, Wei JT, Nair PV, Regan MM, Bueti G, Tang J, Rubin MA, Kearney M, Thompson IM, Sanda MG. Validation in a Multiple Urology Practice Cohort of the Prostate Cancer Prevention Trial Calculator for Predicting Prostate Cancer Detection J Urol 2009 Oct;.

Tangen CM, Goldman BH, Swanson GP, Thompson IM. Biased Hormonal Therapy Duration Analysis Makes Results Uninterpretable J Clin Oncol 2009 Sep;.

Newcomb LF, Brooks JD, Carroll PR, Feng Z, Gleave ME, Nelson PS, Thompson IM, Lin DW. Canary Prostate Active Surveillance Study: Design of a Multi-institutional Active Surveillance Cohort and Biorepository Urology 2009 Sep;.

Sarvis JA, Thompson IM. United States military contributions to the National Cancer Institute Urol Oncol 2009 Sep;27(5):558-561.

Schenk JM, Kristal AR, Neuhouser ML, Tangen CM, White E, Lin DW, Thompson IM. Serum adiponectin, C-peptide and leptin and risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial Prostate 2009 Sep;69(12):1303-1311.

Gong Z, Kristal AR, Schenk JM, Tangen CM, Goodman PJ, Thompson IM. Alcohol consumption, finasteride, and prostate cancer risk: results from the Prostate Cancer Prevention Trial Cancer 2009 Aug;115(16):3661-3669.

Beuten J, Gelfond JA, Martinez-Fierro ML, Weldon KS, Crandall AC, Rojas-Martinez A, Thompson IM, Leach RJ. Association of chromosome 8q variants with prostate cancer risk in Caucasian and Hispanic men Carcinogenesis 2009 Aug;30(8):1372-1379.

Thompson IM, Tangen CM, Goodman PJ, Lucia MS, Klein EA. Chemoprevention of prostate cancer J Urol 2009 Aug;182(2):499-507.

Brawley OW, Ankerst DP, Thompson IM. Screening for prostate cancer CA Cancer J Clin 2009 Jul;59(4):264-273.

Beuten J, Gelfond JA, Franke JL, Weldon KS, Crandall AC, Johnson-Pais TL, Thompson IM, Leach RJ. Single and multigenic analysis of the association between variants in 12 steroid hormone metabolism genes and risk of prostate cancer Cancer Epidemiol Biomarkers Prev 2009 Jun;18(6):1869-1880.

Rittmaster RS, Fleshner NE, Thompson IM. Pharmacological approaches to reducing the risk of prostate cancer Eur Urol 2009 May;55(5):1064-1073.

Ankerst DP, Miyamoto R, Nair PV, Pollock BH, Thompson IM, Parekh DJ. Yearly prostate specific antigen and digital rectal examination fluctuations in a screened population J Urol 2009 May;181(5):2071-2075.

Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E, Crawford ED. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial J Urol 2009 Mar;181(3):956-962.

Kim K, Aronov P, Zakharkin SO, Anderson D, Perroud B, Thompson IM, Weiss RH. Urine metabolomics analysis for kidney cancer detection and biomarker discovery Mol Cell Proteomics 2009 Mar;8(3):558-570.

Swanson GP, Goldman B, Tangen CM, Chin J, Messing E, Canby-Hagino E, Forman JD, Thompson IM, Crawford ED. The prognostic impact of seminal vesicle involvement found at prostatectomy and the effects of adjuvant radiation: data from Southwest Oncology Group 8794 J Urol 2008 Dec;180(6):2453-2457.

Kim K, Aronov P, Zakharkin SO, Anderson D, Perroud B, Thompson IM, Weiss RH. Urine metabolomic analysis for kidney cancer detection and biomarker discovery Mol Cell Proteomics 2008 Nov;.

Sarvis JA, Thompson IM. Prostate cancer chemoprevention: update of the prostate cancer prevention trial findings and implications for clinical practice Curr Oncol Rep 2008 Nov;10(6):529-532.

Thompson IM, Ankerst DP, Etzioni R, Wang T. Its time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer J Urol 2008 Oct;180(4):1219-1222.

Neuhouser ML, Schenk J, Song YJ, Tangen CM, Goodman PJ, Pollak M, Penson DF, Thompson IM, Kristal AR. Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial Prostate 2008 Sep;68(13):1477-1486.

Reed AB, Ankerst DP, Leach RJ, Vipraio G, Thompson IM, Parekh DJ. Total prostate specific antigen stability confirmed after long-term storage of serum at -80C J Urol 2008 Aug;180(2):534-537.

Lucia MS, Darke AK, Goodman PJ, La Rosa FG, Parnes HL, Ford LG, Coltman CA, Thompson IM. Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention Cancer Prev Res (Phila Pa) 2008 Aug;1(3):167-173.

Redman MW, Tangen CM, Goodman PJ, Lucia MS, Coltman CA, Thompson IM. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach Cancer Prev Res (Phila Pa) 2008 Aug;1(3):174-181.

Thompson IM, Tangen CM, Ankerst DP, Chi C, Lucia MS, Goodman P, Parnes H, Coltman CA. The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy J Urol 2008 Aug;180(2):544-547.

Sarvis JA, Thompson IM. Androgens and prevention of prostate cancer Curr Opin Endocrinol Diabetes Obes 2008 Jun;15(3):271-277.

Troyer DA, Tang Y, Bedolla R, Adhvaryu SG, Thompson IM, Abboud-Werner S, Sun LZ, Friedrichs WE, Degraffenried LA. Characterization of PacMetUT1, a recently isolated human prostate cancer cell line Prostate 2008 Jun;68(8):883-892.

Beuten J, Gelfond JA, Byrne JJ, Balic I, Johnson-Pais TL, Thompson IM, Price DK, Leach RJ. CYP1B1 variants are associated with Prostate Cancer in non-Hispanic and Hispanic Caucasians Carcinogenesis 2008 Jun;29(9):1751-1757.

Thompson IM, Tangen CM, Parnes HL, Lippman SM, Coltman CA. Does the level of prostate cancer risk affect cancer prevention with finasteride? Urology 2008 May;71(5):854-857.

Torkko KC, van Bokhoven A, Mai P, Beuten J, Balic I, Byers TE, Hokanson JE, Norris JM, Barn AE, Lucia MS, Thompson IM, Leach RJ. VDR and SRD5A2 polymorphisms combine to increase risk for prostate cancer in both non-Hispanic White and Hispanic White men Clin Cancer Res 2008 May;14(10):3223-3229.

Kristal AR, Arnold KB, Schenk JM, Neuhouser ML, Goodman P, Penson DF, Thompson IM. Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial Am J Epidemiol 2008 Apr;167(8):925-934.

Thompson IM, Tangen CM, Lucia MS. The Prostate Cancer Prevention Trial and the future of chemoprevention BJU Int 2008 Apr;101(8):933-934.

Song Y, Tangen C, Goodman P, Parnes HL, Lucia MS, Thompson IM, Kristal AR. Finasteride, prostate cancer, and weight gain: evidence for genetic or environmental factors that affect cancer outcomes during finasteride treatment Prostate 2008 Feb;68(3):281-286.

Pepe MS, Feng Z, Huang Y, Longton G, Prentice R, Thompson IM, Zheng Y. Integrating the predictiveness of a marker with its performance as a classifier Am J Epidemiol 2008 Feb;167(3):362-368.

Brand TC, Bermejo C, Canby-Hagino E, Troyer DA, Baillargeon J, Thompson IM, Leach RJ, Naylor SL. Association of polymorphisms in TGFB1 and prostate cancer prognosis J Urol 2008 Feb;179(2):754-758.

McLerran D, Grizzle WE, Feng Z, Thompson IM, Bigbee WL, Cazares LH, Chan DW, Dahlgren J, Diaz J, Kagan J, Lin DW, Malik G, Oelschlager D, Partin A, Randolph TW, Sokoll L, Srivastava S, Srivastava S, Thornquist M, Troyer D, Wright GL, Zhang Z, Zhu L, Semmes OJ. SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer Clin Chem 2008 Jan;54(1):53-60.

McLerran D, Grizzle WE, Feng Z, Bigbee WL, Banez LL, Cazares LH, Chan DW, Diaz J, Izbicka E, Kagan J, Malehorn DE, Malik G, Oelschlager D, Partin A, Randolph T, Rosenzweig N, Srivastava S, Srivastava S, Thompson IM, Thornquist M, Troyer D, Yasui Y, Zhang Z, Zhu L, Semmes OJ. Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias Clin Chem 2008 Jan;54(1):44-52.

Heath EI, Kattan MW, Powell IJ, Sakr W, Brand TC, Rybicki BA, Thompson IM, Aronson WJ, Terris MK, Kane CJ, Presti JC, Amling CL, Freedland SJ. The effect of race/ethnicity on the accuracy of the 2001 Partin Tables for predicting pathologic stage of localized prostate cancer Urology 2008 Jan;71(1):151-155.

Reed A, Ankerst DP, Pollock BH, Thompson IM, Parekh DJ. Current age and race adjusted prostate specific antigen threshold values delay diagnosis of high grade prostate cancer J Urology 2007 Dec;.

Parekh DJ, Ankerst DP, Troyer D, Srivastava S, Thompson IM. Biomarkers for prostate cancer detection J Urol 2007 Dec;178(6):2252-2259.

McLerran D, Grizzle WE, Feng Z, Bigbee WL, Banez LL, Cazares LH, Chan DW, Diaz J, Izbicka E, Kagan J, Makehorn DE, Malik G, Oelschlager D, Partin A, Randolph T, Rosenzweig N, Srivastava S, Thompson IM, Thornquist M, Troyer D, Yasui Y, Zhang Z, Zhu L, Semmes OJ. Analytical Validation of Serum Proteomic Profiling for Diagnosis of Prostate Cancer: Sources of Sample Bias Clin Chem 2007 Dec;.

Pepe MS, Feng Z, Huang Y, Longton G, Prentice R, Thompson IM, Zheng Y. Integrating the Predictiveness of a marker with its performances as a classifier Am J Epidemiol 2007 Nov;.

Swanson GP, Thompson IM. Adjuvant radiotherapy for high-risk patients following radical prostatectomy Urol Oncol 2007 Nov;25(6):515-519.

McLerran D, Grizzle WE, Feng Z, Thompson IM, Bigbee WL, Cazares LH, Chan DW, Dahlgren J, Diaz J, Kagan J, Lin D, Malik G, Oelschlager D, Partin A, Randolph T, Sokoll L, Srivastava S, Thornquist M, Troyer D, Wright GL, Zhang Z, Zhu L, Semmes OJ. SELDI-TOF MS Whole Serum Proteomic Profiling with IMAC Surface Does Not Reliably Detect Prostate Cancer Clin Chem 2007 Nov;.

Shook SJ, Beuten J, Torkko KC, Johnson-Pais TL, Troyer DA, Thompson IM, Leach RJ. Association of RNASEL variants with prostate cancer risk in Hispanic Caucasians and African Americans Clin Cancer Res 2007 Oct;13(19):5959-5964.

Parekh DJ, Ankerst DP, Baillargeon J, Higgins B, Platz EA, Troyer D, Hernandez J, Leach RJ, Lokshin A, Thompson IM. Assessment of 54 biomarkers for biopsy-detectable prostate cancer Cancer Epidemiol Biomarkers Prev 2007 Oct;16(10):1966-1972.

Parekh DJ, Ankerst DP, Troyer D, Srivastava S, Thompson IM. Biomarkers for prostate cancer detection J Urology 2007 Oct;.

Lucia MS, Epstein JI, Goodman PJ, Darke AK, Reuter VE, Civantos F, Tangen CM, Parnes HL, Lippman SM, La Rosa FG, Kattan MW, Crawford ED, Ford LG, Coltman CA, Thompson IM. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial J Natl Cancer Inst 2007 Sep;99(18):1375-1383.

Thompson IM. Chemoprevention of prostate cancer: agents and study designs J Urol 2007 Sep;178(3 Pt):9-13.

Thompson IM, Pauler Ankerst D, Chi C, Goodman PJ, Tangen CM, Lippman SM, Lucia MS, Parnes HL, Coltman CA Jr. Prediction of Prostate cancer for patients receiving finasteride: results from the prostate cancer prevention trial J Clin Oncol 2007 Jul;25(21):3076-3081.

Thompson IM. Chemoprevention of prostate cancer: lessons learned BJU Int 2007 Jul;100 S:15-17.

Thompson IM, Lucia MS, Redman MW, Darke A, La Rosa FG, Parnes HL, Lippman SM, Coltman CA. Finasteride decreases the risk of prostatic intraepithelial neoplasia J Urol 2007 Jul;178(1):107-109.

Swanson GP, Carpenter WR, Thompson IM, Crawford ED. Urologists'' attitudes regarding cancer clinical research Urology 2007 Jul;70(1):19-24.

Crawford ED, Thompson IM. Controversies regarding screening for prostate cancer BJU Int 2007 Jul;100 S:5-7.

Moinpour CM, Darke AK, Donaldson GW, Thompson IM, Langley C, Ankerst DP, Patrick DL, Ware JE, Ganz PA, Shumaker SA, Lippman SM, Coltman CA. Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial J Natl Cancer Inst 2007 Jul;99(13):1025-1035.

Abstract

Powel L, Kozlovsky K, Reed A, Thompson IM, Berndt AE, Benton, J. Factors that Influence Patients with Elevated PSA to Choose or Decline Prostate Biopsy; 2009 Dec. (The Aging Male; vol. 12, no. 4).

Sun L, Tang Y, Mishra S, DeGraffenried L, Werner S, Troyer DA, Thompson IM. Inhibition of osteoblastic tumorigenesis of a novel human prostate cancer cell line by the blockade of TGF-beta signaling, Abstract #B108; 2009 Nov. (In: Proceedings of AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston MA).

Troyer DA, Bu H, Wang Y, Martinez AR, Martinez-Fierro M, Hernandez M, Mendez-Meza R, Bedolla RG, Thompson IM, Fan H. Quantitation of TMPRSS2:ERG Fusion Transcripts in Normal Prostate and Prostate Cancers (PC); 2008 Mar.

Review Article

Kumar AP, Graham HL, Robson C, Thompson, IM and Ghosh R. Natural Products: Potential for developing Phellondendron amurense bark extract for prostate cancer management Mini-rev Med Chem 2010 Jan;10:388-397.

Editorial

Leach R, Thompson IM, Thompson, Jr. IM. The dilemma of prostate-specific antigen testing Arch Intern Med 2012 Jun;172(11):835-836.

Not Specified

Thompson IM, Tangen CM, Thompson, Jr. IM. Prostate cancer--uncertainty and a way forward N Engl J Med 2012 Jul;367(3):270-271.

Ankerst DP, Thompson IM, Thompson, Jr. IM. Words of wisdom. Re: Combining 33 genetic variants with prostate-specific antigen for the prediction of prostate cancer: longitudinal study Eur Urol 2012 Jul;62(1):180-180.

Thompson IM, Ankerst DP. The benefits of risk assessment tools for prostate cancer Eur Urol 2012 Apr;61(4):662-663.

Vickers AJ, Till C, Tangen CM, Lilja H, Thompson IM. An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection J Natl Cancer Inst 2011 Mar;103(6):462-469.

Thompson IM, Leach RJ, Ankerst DP. Prostate cancer detection: a view of the future Eur Urol 2011 Feb;59(2):191-193.

Thompson IM, Salem S, Chang SS, Clark PE, Davis R, Herrell SD, Kordan Y, Baumgartner R, Phillips S, Smith JA, Cookson MS, Barocas DA. Tumor volume as a predictor of adverse pathologic features and biochemical recurrence (BCR) in radical prostatectomy specimens: a tale of two methods World J Urol 2011 Feb;29(1):15-20.

Chang BL, Spangler E, Gallagher S, Haiman CA, Henderson B, Isaacs W, Benford ML, Kidd LR, Cooney K, Strom S, Ingles SA, Stern MC, Corral R, Joshi AD, Xu J, Giri VN, Rybicki B, Neslund-Dudas C, Kibel AS, Thompson IM, Leach RJ, Ostrander EA, Stanford JL, Witte J, Casey G, Eeles R, Hsing AW, Chanock S, Hu JJ, John EM, Park J, Stefflova K, Zeigler-Johnson C, Rebbeck TR. Validation of genome-wide prostate cancer associations in men of African descent Cancer Epidemiol Biomarkers Prev 2011 Jan;20(1):23-32.

Dorff TB, Goldman B, Pinski JK, Mack PC, Lara PN, Van Veldhuizen PJ, Quinn DI, Vogelzang NJ, Thompson IM, Hussain MH. Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer Clin Cancer Res 2010 Jun;16(11):3028-3034.

Thompson IM. Editorial comment Urology 2010 Mar;75(3):509-510.

Dombrowski H, Neumaier S, Thompson IM, Wissmann F. EURADOS intercomparison 2006 to harmonise European early warning dosimetry systems Radiat Prot Dosimetry 2009 Jun;135(1):1-20.

Thompson IM, Tangen CM, Klein EA. Is there a standard of care for pathologic stage T3 prostate cancer? J Clin Oncol 2009 Jun;27(18):2898-2899.

Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL, Baker LH, Coltman CA. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT) JAMA 2009 Jan;301(1):39-51.

Kristal AR, Schenk JM, Song Y, Arnold KB, Neuhouser ML, Goodman PJ, Lin DW, Stanczyk FZ, Thompson IM. Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial Am J Epidemiol 2008 Dec;168(12):1416-1424.

Thompson IM, Tangen CM, Kristal AR. Prostate-specific antigen: a misused and maligned prostate cancer biomarker J Natl Cancer Inst 2008 Nov;100(21):1487-1488.

Moinpour CM, Hayden KA, Unger JM, Thompson IM, Redman MW, Canby-Hagino ED, Higgins BA, Sullivan JW, Lemmon D, Breslin S, Crawford ED. Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy J Clin Oncol 2008 Jan;26(1):112-120.

Kantoff PW, Beer TM, D''Amico AV, Dipaola RS, Eisenberger MA, Hussain MH, Kelly WK, Mathew P, Morris MJ, Ryan CJ, Sandler HM, Thompson IM, Carroll PR. Innovations and challenges in prostate cancer: summary statement for the 6th Cambridge Conference J Urol 2007 Sep;178(3 Pt):5-8.

Year	Degree	Discipline	Institution
1988	Clinical Fellowship	Urologic Oncology	Sloan Memorial Ketterring Cancer Center New York , NY
1985	Residency	Urology	Brooke Army Medical Center San Antonio , TX
1981	Internship	Surgery	Brooke Army Medical Center San Antonio , TX
1980	MD	Medicine	Tulane University School of Medicine New Orleans , LA
1976	BS		United States Military Academy West Point , NY

Date	Description	Institution	# Students
3/2010 - Present	High School/Junior High School Student Supervision	Regional

3/2009 - Present	Urology Coding Instruction	UTHSCSA/CTRC	15 students

8/2004 - Present		The University of Texas Health Science Center at San Antonio

1/2003 - Present		The University of Texas Health Science Center at San Antonio

9/1999 - Present	Adv Clin Eval Skills	The University of Texas Health Science Center
Third year medical students recieve a lecture and watch a video of an acutal male urologic physical eaxm. The students are then instructed with volunteer patients on the proper procedure for a Digital Rectal Exam.
1/1999 - Present	Special Topic	The University of Texas Health Science Center
Advanced Clinical Evaluation Skills Course
1/1998 - Present		The University of Texas Health Science Center

1/1998 - Present	Rotation Student Supervision	University Hospital

1/1998 - Present	Intro to Clinical Surgery	The University of Texas Health Science Center
Intro to Surgery (Urology)
1/1998 - Present	Special Topic	The University of Texas Health Science Center
Student Conference
1/1998 - Present	Rotation Student Supervision	Audie L. Murphy Veterans Hospital Administration

1/1998 - Present		University Hospital

Federal
Funding Agency	NIH
Title	San Antonio Center of Biomarkers of Risk for Prostrate Cancer (SABOR)
Status	Complete
Period	4/2000 - 6/2015
Role	Principal Investigator
Grant Detail
Funding Agency	NCI-NIH
Title	Improving Prostate Biopsy Efficiency
Status	Active
Period	7/2010 - 6/2015
Role	Co-Investigator
Grant Detail
Funding Agency	National Cancer Institute
Title	The Prostate Cancer Prevention Trial Long Term Follow Up
Status	Active
Period	6/2005 - 5/2011
Role	Co-Investigator
Grant Detail	The goal of this project is to obtain long term follow up information on participants for the Prostate Cancer Prevention Trial.
Funding Agency	NIH/NCI
Title	Southwest Oncology Group Operations Office
Status	Active
Period	8/2008 - 12/2010
Role	Co-Investigator
Grant Detail
State
Funding Agency	CPRIT
Title	Texas Cancer Diagnostics Pipeline Consortium
Status	Active
Period	8/2010 - 7/2013
Role	Co-Investigator
Grant Detail

Faculty

FAQ

Suggestions

Thompson, Jr., Ian Murchie Jr.

Prostate Cancer

Quality of Life

Urologic Oncology

Journal Article

Abstract

Review Article

Editorial

Not Specified

Federal

State